Table 1.
Clinical and pathological features of the study population.
| Case ID (Age) |
Gestational Week at Diagnosis | Histology | FIGO Stage 2018 |
Tumor Size (mm) |
NACT | Response to CT | Tumor Size after NACT (mm) | Treatment | Pathological Response | Adjuvant Treatment | Recurrence | Maternal Outcome | FUP Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (38 y) |
18 | SCC | IIA1 | 40 | 4 x cisplatin 75 mg/mg q 21 | PR | 12 | (1) NACT (2) CS (34 w) (3) RH + BSO + PLND 1 month later |
pR2 LVSI+ N− Margins+ |
RT-CT + BRT | Yes | DOD | 31 |
| 2 (42 y) |
13 | SCC | IIA1 | 25 | 5 x cisplatin 75 mg/mg + paclitaxel 135 mg/mq q 21 |
PR | 16 | (1) NACT (2) CS + RH + BSO + PLND (31 w) |
pR2 LVSI+ N− Margins− |
RT | No | Alive | 36 |
| 3 (34 y) |
18 | SCC | IB2 | 41 | 1 x cisplatin 75 mg/mg + paclitaxel 135 mg/mq q 21 3 x cisplatino 75 mg/mg + paclitaxel 105 mg/mq q 21 |
CR | 13 | (1) NACT (2) CS + RH + BSO + PLND (34 w) |
pR0 LVSI− N− Margins− |
No | No | Alive | 74 |
| 4 (34 y) |
25 | SCC | IIIC1 | 70 | 2 x cisplatin 75 mg/mg + paclitaxel 135 mg/mq q 21 |
PR | 40 | (1) NACT (2) CS + RH + BS + PLND (35 w) |
pR2 LVSI+ N− Margins− |
RT-CT | No | Alive | 91 |
| 5 (36 y) |
20 | SCC | IB3 | 47 | 4 x cisplatin 75 mg/mg + paclitaxel 135 mg/mq q 21 |
PR | 31 | (1) NACT (2) CS + RH + BSO + PLND (34 w) |
pR2 LVSI+ N− Margins− |
RT-CT + BRT | No | Alive | 67 |
| 6 (37 y) |
15 | SCC | IIIC1 | 50 | 4 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 |
PR | 41 | (1) NACT (2) CS + RH + BSO + PLND (34 w) |
pR2 LVSI+ N+ Margins− |
RT-CT | No | Alive | 46 |
| 7 (33 y) |
23 | SCC | IIIC1 | 80 | 3 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 |
PD | 78 | (1) NACT (2) CS (32 w) (3) RT-CHT (4) RH + BSO + PLND + ALND 4 months after |
pR1 LVSI− N− Margins− |
No | Yes | Alive | 41 |
| 8 (41 y) |
12 | SCC | IB3 | 53 | 1 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 3 x carboplatin 4AUC + paclitaxel 135 mg/mq q 21 |
CR | 0 | (1) NACT (2) CS + RH + BS + PLND (34 w) |
pR0 LVSI− N− Margins− |
No | No | Alive | 40 |
| 9 (27 y) |
23 | SCC | IB3 | 49 | 2 x carboplatino 4AUC + paclitaxel 175 mg/mq q 21 1x carboplatin 4AUC |
SD | 49 | (1) NACT (2) CS + RH + BS + PLND (36 w) |
pR2 LVSI+ N− Margins− |
Refused | No | Alive | 36 |
| 10 (35 y) |
23 | SCC | IIA2 | 49 | 2 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 |
SD | 45 | (1) NACT (2) CS + RH + BSO + PLND (34 w) |
pR2 LVSI+ N− Margins− |
RT + BRT | No | Alive | 23 |
| 11 (36 y) |
13 | SCC | IIIC1 | 50 | 4 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 1 x carboplatin 4 AUC |
PR | 34 | (1) NACT (2) CS + RH + BSO + PLND (36 w) |
pR2 LVSI+ N+ Margins− |
RT-CT + BRT | No | Alive | 20 |
| 12 (35 y) |
5 | SCC | IIIC1 | 37 | 6 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 |
PR | 31 | (1) PLND + ALND (11 w) (2) NACT (3) CS + RH + BSO (34 w) |
N+ pR2 LVSI+ Margins+ |
RT-CT + BRT | No | Alive | 15 |
| 13 (39 y) |
21 | SCC | IB2 | 36 | 1 x carboplatin 5AUC + paclitaxel 175 mg/mq q 21 1 x carboplatin 4 AUC + paclitaxel 175 mg/mq |
PR | 15 | (1) NACT (2) CS + RH + BSO + PLND (35 w) |
pR1 LVSI− N− Margins− |
No | No | Alive | 9 |
ALND = aortic lymph node dissection; BRT = brachytherapy; BS = bilateral salpingectomy; BSO = bilateral salpingo-oophorectomy; CT = chemotherapy; CR, complete response; CS = cesarean section; DOD, death of disease; FIGO, International Federation of Gynecology and Obstetrics; FUP = follow-up; NACT = neoadjuvant chemotherapy; PD, progressive disease; PLND = pelvic lymph node dissection; PR = partial response; pR0 = complete disappearance of tumor in the cervix; pR1 = residual disease with ≤3 mm stromal invasion, including in situ carcinoma; pR2 = persistent residual disease with >3 mm stromal invasion on surgical specimen; RH = radical hysterectomy; RT = external-beam radiotherapy; SCC = squamous cell carcinoma; SD = stable disease.